4//SEC Filing
KAKKIS EMIL D 4
Accession 0001209191-24-002989
CIK 0001515673other
Filed
Feb 7, 7:00 PM ET
Accepted
Feb 8, 3:49 PM ET
Size
6.3 KB
Accession
0001209191-24-002989
Insider Transaction Report
Form 4
KAKKIS EMIL D
DirectorPresident & CEO10% Owner
Transactions
- Sale
Common Stock
2024-02-07$45.00/sh−30,000$1,350,000→ 539,770 total
Holdings
- 2,263,985(indirect: By Trust)
Common Stock
Footnotes (3)
- [F1]The sales reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person prior to February 27, 2023.
- [F2]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $44.69 to $45.87 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range.
- [F3]Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions.
Documents
Issuer
Ultragenyx Pharmaceutical Inc.
CIK 0001515673
Entity typeother
Related Parties
1- filerCIK 0001248093
Filing Metadata
- Form type
- 4
- Filed
- Feb 7, 7:00 PM ET
- Accepted
- Feb 8, 3:49 PM ET
- Size
- 6.3 KB